NeurAxis Reports Second Quarter 2024 Financial Results

Aug 9, 2024 · Second Quarter 2024 Financial Results Revenues in the second quarter of 2024 were $611.5 thousand, down 5.3% compared to $646.0 thousand in the second quarter of …

CouponFollow Extension

3%
OFF

NeurAxis Reports Second Quarter 2024 Financial Results

2 weeks from now

Aug 9, 2024 · Second Quarter 2024 Financial Results Revenues in the second quarter of 2024 were $611.5 thousand, down 5.3% compared to $646.0 thousand in the second quarter of …

neuraxis.com

7%
OFF

NeurAxis Reports First Quarter 2024 Financial Results

2 weeks from now

May 22, 2024 · First Quarter 2024 Financial Results. Revenues in the first quarter of 2024 were $646.6 thousand, down 19.7% compared to $805.1 thousand in the first quarter of 2023. The …

neuraxis.com

39%
OFF

NeurAxis Reports Strong Third Quarter 2024 Financial Results …

2 weeks from now

3 days ago · Gross profit in the third quarter of 2024 was $570 thousand, a 39% increase compared to $410 thousand in the third quarter of 2023 due to the higher sales volume.

morningstar.com

45%
OFF

NeurAxis Reports Strong Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Operating loss in the third quarter of 2024 was $1.7 million, a decrease of 45% compared to $3.0 million in the third quarter of 2023. The improvement was primarily due to …

businessinsider.com

$57
OFF

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 …

2 weeks from now

2 days ago · Net loss was C$57.2 million for the quarter ended September 30, 2024, which includes a non-recurring, non-cash component related to share-based compensation, …

businesswire.com

9%
OFF

NeurAxis Reports Second Quarter 2024 Financial Results

2 weeks from now

Aug 10, 2024 · Gross profit in the second quarter of 2024 was $538.0 thousand, a 6.9% decrease compared to $578.2 thousand in the second quarter of 2023 due to the lower sales volume. …

yahoo.com

$8
OFF

Elevai Labs Inc. Reports Financial Results For The Second Fiscal ...

2 weeks from now

1 day ago · Financial Results for the Three and Six Months Ended June 30, 2024 $8 Million Public Offering: Elevai raised $8 million in a successful public offering to capitalize the business and …

morningstar.com

40%
OFF

NeurAxis Reports Strong Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · NeurAxis (NYSE: NRXS) reported strong Q3 2024 results with revenues increasing 40% to $667,000 compared to Q3 2023. Operating loss improved by 45% to $1.7 million. The …

stocktitan.net

81%
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Third Quarter 2024 Financial Highlights Total net product revenue for the third quarter of 2024 was $104.8 million, representing 81% year-over-year growth. Total net product …

yahoo.com

7%
OFF

Zoomcar Reports Significant Profitability Improvement In Its …

2 weeks from now

21 hours ago · The number of bookings rose by 7%, from 97,970 in the previous quarter to 105,160, in the quarter ended September 30, 2024, driven by 1.5x increase in the guest …

prnewswire.com

40%
OFF

NeurAxis Reports Strong Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Third Quarter 2024 Financial Results. Revenues in the third quarter of 2024 were $667 thousand, up 40% compared to $477 thousand in the third quarter of 2023. Unit sales …

stockhouse.com

3%
OFF

NeurAxis Reports Second Quarter 2024 Financial Results

2 weeks from now

Aug 9, 2024 · Second Quarter 2024 Financial Results Revenues in the second quarter of 2024 were $611.5 thousand, down 5.3% compared to $646.0 thousand in the second quarter of 2023.

morningstar.com

FAQs about NeurAxis Reports Second Quarter 2024 Financial Results Coupon?

How did Neuraxis perform in 3q24?

Management Commentary Brian Carrico, Chief Executive Officer of NeurAxis, commented, “We are excited about our strong performance in the 3Q24, as revenues increased 40% year over year. Demand for our IB-Stim product is accelerating, as unit sales grew 50% in the third quarter. ...

What did Axsome Therapeutics do in Q3 2024?

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2024 and provided a general business update. ...

Who is Neuraxis?

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. ...

What happened in the third quarter of 2024?

Revenues in the third quarter of 2024 were $667 thousand, up 40% compared to $477 thousand in the third quarter of 2023. Unit sales increased approximately 50%, partially offset by discounts given to patients without insurance coverage via the Company’s financial assistance program. ...

What was the net loss in the third quarter of 2024?

The net loss in the third quarter of 2024 was $1.8 million, a decrease of 80% compared to $8.6 million in the third quarter of 2023. The decrease was primarily due to the lower operating loss and the absence of debt discount, issuance cost and debt extinguishment charges triggered by the Company’s IPO in the third quarter of 2023. ...

Why did the company's operating loss decrease in 2024?

The decrease was primarily due to the lower operating loss and the absence of debt discount, issuance cost and debt extinguishment charges triggered by the Company’s IPO in the third quarter of 2023. While cash on hand as of September 30, 2024 was $261 thousand, the Company entered into a $5.0 million investment agreement on November 9, 2024. ...